MARE NOSTRUM : Rapport financier annuel 2023
31 juil. 2024 12h41 HE
|
MARE NOSTRUM
Rapport financier annuel 2023 de Mare Nostrum pour l'exercice clos le 31 décembre 2023.
Pièce jointe
MARE NOSTRUM - RFA 2023 complet
...
BD² ANNOUNCES NEW FUNDING OPPORTUNITIES TO JOIN LANDMARK BIPOLAR DISORDER RESEARCH AND CLINICAL CARE NETWORK
18 juil. 2024 08h00 HE
|
BD²: Breakthrough Discoveries for Thriving with Bipolar Disorder
Washington, DC, July 18, 2024 (GLOBE NEWSWIRE) -- BD²: Breakthrough Discoveries for Thriving with Bipolar Disorder today announced its second call for applications for clinic sites to join the BD²...
Correction: ORAPI : Mise à disposition du Rapport Financier Annuel 2023
18 avr. 2024 11h45 HE
|
ORAPI
Communiqué de presse Lyon – Saint-Vulbas, le 18 avril 2024 à 17h30 Mise à disposition du rapport financier annuel 2023 ORAPI annonce avoir mis à la disposition du public et déposé auprès...
ORAPI : Mise à disposition du Rapport Financier Annuel 2023
18 avr. 2024 11h30 HE
|
ORAPI
Communiqué de presse Lyon – Saint-Vulbas, le 18 avril 2023 à 17h30 Mise à disposition du rapport financier annuel 2023 ORAPI annonce avoir mis à la disposition du public et déposé auprès de...
HIOLLE INDUSTRIES: mise à disposition du Rapport Financier Annuel 2020
30 avr. 2021 11h35 HE
|
HIOLLE INDUSTRIES
COMMUNIQUÉDE MISE A DISPOSITIONDU RAPPORT FINANCIER ANNUEL 2020 La société annonce avoir procédé en date du 30 Avril 2021 à la diffusion effective et intégrale et au dépôt auprès de l’Autorité des...
SPRINT® PNS System Demonstrates the Important Role of the Multifidus in Treating Recurrent Low Back Pain Following RFA
02 mars 2021 10h45 HE
|
SPR Therapeutics, Inc.
CLEVELAND, March 02, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, announced publication of clinical data evaluating the impact of...
Celsion Reports that Sufficient Events Have Been Reached for the Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
15 avr. 2020 08h30 HE
|
Celsion CORP
Independent Data Monitoring Committee is Expected to Meet in July 2020 to Evaluate Overall Survival Data LAWRENCEVILLE, N.J., April 15, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:...
Interpace Biosciences Announces Collaborative Study with University of North Carolina to Assess the Use BarreGEN® after Ablation of Dysplastic Barrett’s Esophagus
06 janv. 2020 06h55 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG), a leader in enabling personalized medicine, today announced that the Company’s wholly-owned subsidiary,...
Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase III Study of ThermoDox® in Primary Liver Cancer
05 août 2019 09h00 HE
|
Celsion CORP
Independent Data Monitoring Committee to Meet in October to Evaluate Interim Trial Data LAWRENCEVILLE, N.J., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology...
RFA and Seclore Announce Strategic Partnership to Deliver Data-Centric Security to Firms Worldwide
01 nov. 2017 08h00 HE
|
Seclore
NEW YORK and SUNNYVALE, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- RFA and Seclore have agreed to integrate Seclore’s leading, data-centric security Rights Management solution into RFA’s managed...